Pluri Introduces Groundbreaking Immune Cell Expansion Technology, Secures New US Patent
Portfolio Pulse from Benzinga Newsdesk
Pluri Inc. (NASDAQ:PLUR) announced a groundbreaking immune cell expansion technology and secured a new U.S. patent for it. This novel method, using proprietary 3D cell expansion technology, mimics the natural environment of immune cells, offering a promising solution for advanced cell-based therapies.
April 08, 2024 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pluri Inc. introduced a novel immune cell expansion technology and secured a new U.S. patent, potentially revolutionizing cell-based therapies.
The introduction of a groundbreaking technology and securing a patent typically signals potential growth and innovation, attracting investor interest. This technology could place Pluri Inc. at the forefront of cell-based therapy advancements, likely leading to increased investor confidence and potentially boosting stock prices in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100